William Blair Has Bearish Estimate for RARE Q4 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Investment analysts at William Blair dropped their Q4 2026 earnings estimates for shares of Ultragenyx Pharmaceutical in a report released on Monday, July 14th. William Blair analyst S. Corwin now expects that the biopharmaceutical company will post earnings of $0.99 per share for the quarter, down from their previous forecast of $1.09. William Blair has a “Outperform” rating and a $65.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share.

Several other analysts have also recently weighed in on the stock. Wells Fargo & Company dropped their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. Guggenheim reiterated a “buy” rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research report on Monday. Morgan Stanley dropped their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.64.

Ultragenyx Pharmaceutical Stock Down 6.9%

Shares of Ultragenyx Pharmaceutical stock opened at $27.20 on Tuesday. Ultragenyx Pharmaceutical has a twelve month low of $26.85 and a twelve month high of $60.37. The company has a 50-day simple moving average of $36.12 and a two-hundred day simple moving average of $38.53. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -4.63 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. During the same quarter last year, the firm earned ($2.03) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.0% compared to the same quarter last year.

Insider Activity

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director directly owned 15,344 shares of the company’s stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 3,167 shares of company stock worth $118,824. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in RARE. Deep Track Capital LP acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $27,493,000. Dark Forest Capital Management LP acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $459,000. First Light Asset Management LLC increased its position in Ultragenyx Pharmaceutical by 1.1% in the 4th quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company’s stock valued at $32,125,000 after acquiring an additional 8,505 shares during the period. Stifel Financial Corp increased its position in Ultragenyx Pharmaceutical by 13.5% in the 4th quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company’s stock valued at $1,001,000 after acquiring an additional 2,835 shares during the period. Finally, Alyeska Investment Group L.P. increased its position in Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company’s stock valued at $60,570,000 after acquiring an additional 269,733 shares during the period. 97.67% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.